JP2003532640A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003532640A5 JP2003532640A5 JP2001574119A JP2001574119A JP2003532640A5 JP 2003532640 A5 JP2003532640 A5 JP 2003532640A5 JP 2001574119 A JP2001574119 A JP 2001574119A JP 2001574119 A JP2001574119 A JP 2001574119A JP 2003532640 A5 JP2003532640 A5 JP 2003532640A5
- Authority
- JP
- Japan
- Prior art keywords
- apomorphine
- patient
- norapomorphine
- administering
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims 16
- 229960004046 apomorphine Drugs 0.000 claims 14
- 238000000034 method Methods 0.000 claims 8
- MHPQCGZBAVXCGA-GFCCVEGCSA-N (6ar)-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol Chemical compound N1CCC2=CC=CC3=C2[C@H]1CC1=CC=C(O)C(O)=C13 MHPQCGZBAVXCGA-GFCCVEGCSA-N 0.000 claims 7
- 201000001880 Sexual dysfunction Diseases 0.000 claims 6
- 231100000872 sexual dysfunction Toxicity 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 3
- 230000002708 enhancing effect Effects 0.000 claims 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 150000008064 anhydrides Chemical class 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 150000002170 ethers Chemical class 0.000 claims 2
- -1 glucuronates Chemical class 0.000 claims 2
- 150000002373 hemiacetals Chemical class 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims 2
- 238000010276 construction Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19565000P | 2000-04-07 | 2000-04-07 | |
| US60/195,650 | 2000-04-07 | ||
| PCT/US2001/040393 WO2001076602A1 (en) | 2000-04-07 | 2001-03-29 | Apomorphine derivatives and methods for their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003532640A JP2003532640A (ja) | 2003-11-05 |
| JP2003532640A5 true JP2003532640A5 (OSRAM) | 2005-05-26 |
Family
ID=22722192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001574119A Withdrawn JP2003532640A (ja) | 2000-04-07 | 2001-03-29 | アポモルヒネ誘導体及びその使用方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6506765B2 (OSRAM) |
| EP (1) | EP1284735A4 (OSRAM) |
| JP (1) | JP2003532640A (OSRAM) |
| KR (1) | KR20030036157A (OSRAM) |
| CN (1) | CN1471395A (OSRAM) |
| AU (1) | AU2001255818A1 (OSRAM) |
| BG (1) | BG107217A (OSRAM) |
| BR (1) | BR0109515A (OSRAM) |
| CA (1) | CA2405419A1 (OSRAM) |
| CZ (1) | CZ20023637A3 (OSRAM) |
| HU (1) | HUP0301773A3 (OSRAM) |
| IL (1) | IL151614A0 (OSRAM) |
| MX (1) | MXPA02009904A (OSRAM) |
| NO (1) | NO20024806D0 (OSRAM) |
| PL (1) | PL361672A1 (OSRAM) |
| SK (1) | SK15772002A3 (OSRAM) |
| WO (1) | WO2001076602A1 (OSRAM) |
| ZA (1) | ZA200207489B (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0002934D0 (sv) * | 2000-08-17 | 2000-08-17 | Axon Biochemicals Bv | New aporphine esters and in their use in therapy |
| SE0102036D0 (sv) * | 2001-06-08 | 2001-06-08 | Axon Biochemicals Bv | Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof |
| US20040002482A1 (en) * | 2000-08-30 | 2004-01-01 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
| US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
| US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| CA2446904A1 (en) * | 2001-05-24 | 2003-04-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
| CA2479372A1 (en) * | 2002-03-19 | 2003-10-02 | Michael Holick | Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof |
| WO2004069167A2 (en) * | 2003-01-31 | 2004-08-19 | Nastech Pharmaceutical Company Inc. | Method and compositions for treating male infertility |
| US20060178394A1 (en) * | 2003-04-14 | 2006-08-10 | Staniforth John N | Pharmaceutical compositions comprising apomorphine for pulmonary inhalation |
| US20040204439A1 (en) * | 2003-04-14 | 2004-10-14 | Staniforth John Nicholas | Composition, device, and method for treating sexual dysfunction via inhalation |
| GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| US20070088012A1 (en) * | 2005-04-08 | 2007-04-19 | Woun Seo | Method of treating or preventing type-2 diabetes |
| PT2450041T (pt) | 2005-10-12 | 2018-11-16 | Unimed Pharmaceuticals Llc | Gel de testosterona melhorado e método para a sua utilização |
| GB2437488A (en) * | 2006-04-25 | 2007-10-31 | Optinose As | Pharmaceutical oily formulation for nasal or buccal administration |
| GB0721394D0 (en) * | 2007-10-31 | 2007-12-12 | Vectura Group Plc | Compositions for trating parkinson's disease |
| US10729710B2 (en) | 2017-11-24 | 2020-08-04 | H. Lundbeck A/S | Catecholamine prodrugs for use in the treatment of Parkinson's disease |
| US11168056B2 (en) | 2019-05-20 | 2021-11-09 | H. Lundbeck A/S | Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol |
| US11130775B2 (en) | 2019-05-20 | 2021-09-28 | H. Lundbeck A/S | Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11104697B2 (en) | 2019-05-20 | 2021-08-31 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11111263B2 (en) | 2019-05-20 | 2021-09-07 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| EP3972970A1 (en) | 2019-05-21 | 2022-03-30 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's disease |
| WO2020234277A1 (en) | 2019-05-21 | 2020-11-26 | H. Lundbeck A/S | Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease |
| EP3972971A1 (en) | 2019-05-21 | 2022-03-30 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's diseases |
| EP3972959A1 (en) | 2019-05-21 | 2022-03-30 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's disease |
| US20240335379A1 (en) * | 2021-08-05 | 2024-10-10 | Zydus Lifesciences Limited | Stable pharmaceutical compositions of apomorphine |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4127118B1 (en) | 1977-03-16 | 1995-12-19 | Alvaro Latorre | Method of effecting and enhancing an erection |
| US4521421A (en) * | 1983-09-26 | 1985-06-04 | Eli Lilly And Company | Treatment of sexual dysfunction |
| US4801587A (en) | 1987-03-02 | 1989-01-31 | Gene Voss | Impotence ointment |
| US5256652A (en) | 1987-11-12 | 1993-10-26 | Pharmedic Co. | Topical compositions and methods for treatment of male impotence |
| DK0689438T3 (da) | 1993-03-26 | 2003-09-29 | Franciscus Wilhelmus He Merkus | Farmaceutiske præparater til intranasal administration af apomorfin |
| ES2143049T3 (es) | 1994-04-22 | 2000-05-01 | Pentech Pharmaceuticals Inc | Formas sublinguales de dosificacion que contienen apomorfina y su uso para el tratamiento de la disfuncion erectil. |
| US5562917A (en) | 1994-12-23 | 1996-10-08 | Pentech Pharmaceuticals, Inc. | Transdermal administration of apomorphine |
| US5624677A (en) | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| US5888534A (en) | 1995-06-13 | 1999-03-30 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| DK0914097T3 (da) | 1996-03-12 | 2002-04-29 | Alza Corp | Sammensætning og doseringsform omfattende opioid antagonist |
| GB9700878D0 (en) | 1997-01-17 | 1997-03-05 | Scherer Ltd R P | Dosage forms and method for ameliorating male erectile dysfunction |
| US5925629A (en) * | 1997-10-28 | 1999-07-20 | Vivus, Incorporated | Transurethral administration of androgenic agents for the treatment of erectile dysfunction |
| WO1999027905A1 (en) | 1997-12-02 | 1999-06-10 | West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited | Compositions for nasal administration |
| US5945117A (en) * | 1998-01-30 | 1999-08-31 | Pentech Pharmaceuticals, Inc. | Treatment of female sexual dysfunction |
| EP1089736A2 (en) * | 1998-06-22 | 2001-04-11 | Queen's University At Kingston | Method and compositions for the treatment or amelioration of female sexual dysfunction |
| IT1299566B1 (it) * | 1998-07-17 | 2000-03-16 | Ifi Istituto Farmacoterapico I | Cerotto transdermico e composizioni farmaceutiche comprendenti r (-)- norapropilapomorfina cloridrato e/o s (+) - norapropilapomorfina |
| US5994363A (en) | 1998-08-24 | 1999-11-30 | Pentech Pharmaceuticals, Inc. | Amelioration of apomorphine adverse effects |
| MXPA01011480A (es) * | 1999-05-13 | 2002-06-04 | Unihart Corp | Composiciones farmaceuticas que comprenden apocodeina y/o sus derivados. |
-
2001
- 2001-03-29 HU HU0301773A patent/HUP0301773A3/hu unknown
- 2001-03-29 CZ CZ20023637A patent/CZ20023637A3/cs unknown
- 2001-03-29 SK SK1577-2002A patent/SK15772002A3/sk not_active Application Discontinuation
- 2001-03-29 CA CA002405419A patent/CA2405419A1/en not_active Abandoned
- 2001-03-29 PL PL01361672A patent/PL361672A1/xx not_active Application Discontinuation
- 2001-03-29 EP EP01929027A patent/EP1284735A4/en not_active Withdrawn
- 2001-03-29 WO PCT/US2001/040393 patent/WO2001076602A1/en not_active Ceased
- 2001-03-29 BR BR0109515-3A patent/BR0109515A/pt not_active IP Right Cessation
- 2001-03-29 US US09/821,236 patent/US6506765B2/en not_active Expired - Fee Related
- 2001-03-29 IL IL15161401A patent/IL151614A0/xx unknown
- 2001-03-29 AU AU2001255818A patent/AU2001255818A1/en not_active Abandoned
- 2001-03-29 KR KR1020027013436A patent/KR20030036157A/ko not_active Withdrawn
- 2001-03-29 MX MXPA02009904A patent/MXPA02009904A/es unknown
- 2001-03-29 CN CNA01815168XA patent/CN1471395A/zh active Pending
- 2001-03-29 JP JP2001574119A patent/JP2003532640A/ja not_active Withdrawn
-
2002
- 2002-09-18 ZA ZA200207489A patent/ZA200207489B/xx unknown
- 2002-10-04 NO NO20024806A patent/NO20024806D0/no not_active Application Discontinuation
- 2002-10-24 BG BG107217A patent/BG107217A/bg unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003532640A5 (OSRAM) | ||
| JP2021063088A5 (OSRAM) | ||
| JP2005526107A5 (OSRAM) | ||
| JP2003501488A5 (OSRAM) | ||
| JP2003535094A5 (OSRAM) | ||
| JP2012525393A5 (OSRAM) | ||
| JP2019515908A5 (OSRAM) | ||
| IL176107A0 (en) | Azabicyclic heterocycles as cannabinoid receptor modulators | |
| JP2001525359A5 (OSRAM) | ||
| SG169233A1 (en) | Pharmaceutical compositions comprising apomorphine for pulmonary inhalation | |
| MXPA01006474A (es) | Derivados colquinol como agentes perjudiciales vasculares. | |
| JP2004525142A5 (OSRAM) | ||
| JP2008523098A5 (OSRAM) | ||
| JP2004534769A5 (OSRAM) | ||
| DE60316779D1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| JP2020507589A5 (OSRAM) | ||
| JP2001526218A5 (OSRAM) | ||
| EP1153924A3 (en) | Substituted 1,3-oxathiolanes with antiviral properties | |
| JP2005525991A5 (OSRAM) | ||
| JP2005526773A5 (OSRAM) | ||
| JP2003520208A5 (OSRAM) | ||
| JP2002506864A5 (OSRAM) | ||
| JP2002509154A5 (OSRAM) | ||
| JP2012504584A5 (OSRAM) | ||
| JPH1036365A5 (OSRAM) |